Skip to main content
Yang Shi, MD, Pathology, Bronx, NY, Montefiore Medical Center

YangShiMD

Pathology Bronx, NY

Hematopathology, Anatomic Pathology, Clinical Pathology

Pathology Resident, Duke University Medical Center

Dr. Shi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shi's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalResidency, Pathology-Anatomic and Clinical, 2012 - 2014
  • University of California (Irvine)
    University of California (Irvine)Residency, Pathology-Anatomic and Clinical, 2010 - 2014
  • China Medical University Shenyang
    China Medical University ShenyangClass of 1999, MD

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2013 - 2025
  • NY State Medical License
    NY State Medical License 2015 - 2024
  • NC State Medical License
    NC State Medical License 2012 - 2014
  • American Board of Pathology Pathology - Anatomic/Pathology - Clinical
  • American Board of Pathology Pathology - Hematology

Publications & Presentations

PubMed

Press Mentions

  • Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
    Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate EndpointNovember 11th, 2021
  • Flock of New Folds Fills in Tauopathy Family Tree
    Flock of New Folds Fills in Tauopathy Family TreeOctober 5th, 2021
  • Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer
    Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial CancerAugust 26th, 2021
  • Join now to see all

Hospital Affiliations